Abdera has reported initial data from a phase i trial of a radiopharmaceutical therapy. The therapy, which targets dll3, has received fda fast track designation for the treatment of extensive-stage small cell lung cancer. Abdera is expected to present updates on its radiopharmaceutical development pipeline at various conferences.